Martin Ihln, Denis Poltoradnev, Mabel Rodriguez, Filip Španiel, Miloslav Kopeček
{"title":"The relationship between 25-hydroxy vitamin D serum level and memory in patients with a first episode of schizophrenia spectrum disorder.","authors":"Martin Ihln, Denis Poltoradnev, Mabel Rodriguez, Filip Španiel, Miloslav Kopeček","doi":"10.1159/000545815","DOIUrl":null,"url":null,"abstract":"<p><p>The relationship between vitamin D levels and cognition in young patients with schizophrenia remains incompletely understood. We explored the association between serum 25-hydroxy vitamin D concentration and long-term memory (i.e., 30-minute delayed recall in the Rey Auditory Verbal Learning Test) in patients with first-episode schizophrenia. The body mass index was measured due to the accumulation of vitamin D in fat. Forty six male participants aged 20.9±2.3 years old with first-episode schizophrenia spectrum disorder were recruited. The median body mass index was 24.1, 25-hydroxy vitamin D was 39.3 nmol/L. The mean delayed recall was 7.6±3.4 words. Serum 25-hydroxy vitamin D concentration and memory performance were below the normative values for healthy adults. 25-hydroxy vitamin D concentrations and ten clinical variables were included as independent variables and delayed recall values were included as dependent variables in the multiple regression analysis. Regression analysis revealed a statistically significant link between 25-hydroxy vitamin D concentration, benzodiazepine use and delayed recall, but not for other clinical variables. We found a positive association between 25-hydroxy vitamin D serum concentration and delayed recall in patients with first-episode schizophrenia, supporting a need for interventional study investigating vitamin D supplementation for the cognition of patients with schizophrenia. A negative association between benzodiazepine intake and memory performance calls for attention to minimalize benzodiazepine use.</p>","PeriodicalId":19239,"journal":{"name":"Neuropsychobiology","volume":" ","pages":"1-16"},"PeriodicalIF":2.3000,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neuropsychobiology","FirstCategoryId":"102","ListUrlMain":"https://doi.org/10.1159/000545815","RegionNum":4,"RegionCategory":"心理学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"NEUROSCIENCES","Score":null,"Total":0}
引用次数: 0
Abstract
The relationship between vitamin D levels and cognition in young patients with schizophrenia remains incompletely understood. We explored the association between serum 25-hydroxy vitamin D concentration and long-term memory (i.e., 30-minute delayed recall in the Rey Auditory Verbal Learning Test) in patients with first-episode schizophrenia. The body mass index was measured due to the accumulation of vitamin D in fat. Forty six male participants aged 20.9±2.3 years old with first-episode schizophrenia spectrum disorder were recruited. The median body mass index was 24.1, 25-hydroxy vitamin D was 39.3 nmol/L. The mean delayed recall was 7.6±3.4 words. Serum 25-hydroxy vitamin D concentration and memory performance were below the normative values for healthy adults. 25-hydroxy vitamin D concentrations and ten clinical variables were included as independent variables and delayed recall values were included as dependent variables in the multiple regression analysis. Regression analysis revealed a statistically significant link between 25-hydroxy vitamin D concentration, benzodiazepine use and delayed recall, but not for other clinical variables. We found a positive association between 25-hydroxy vitamin D serum concentration and delayed recall in patients with first-episode schizophrenia, supporting a need for interventional study investigating vitamin D supplementation for the cognition of patients with schizophrenia. A negative association between benzodiazepine intake and memory performance calls for attention to minimalize benzodiazepine use.
期刊介绍:
The biological approach to mental disorders continues to yield innovative findings of clinical importance, particularly if methodologies are combined. This journal collects high quality empirical studies from various experimental and clinical approaches in the fields of Biological Psychiatry, Biological Psychology and Neuropsychology. It features original, clinical and basic research in the fields of neurophysiology and functional imaging, neuropharmacology and neurochemistry, neuroendocrinology and neuroimmunology, genetics and their relationships with normal psychology and psychopathology. In addition, the reader will find studies on animal models of mental disorders and therapeutic interventions, and pharmacoelectroencephalographic studies. Regular reviews report new methodologic approaches, and selected case reports provide hints for future research. ''Neuropsychobiology'' is a complete record of strategies and methodologies employed to study the biological basis of mental functions including their interactions with psychological and social factors.